

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-40 (cancelled)

Claim 41 (new): An isolated peptide less than 15 amino acids in length comprising an oligopeptide selected from the group consisting of:

GIMIGVLVGV (SEQ ID NO:149);

IMIGVLVGV (SEQ ID NO:193);

IMIGVLVGVA (SEQ ID NO:194);

LLTFWNPPT (SEQ ID NO:224);

VLYGPDAPTI (SEQ ID NO:428);

YLWWVNGQSL (SEQ ID NO:449); and

YLWWVNNQSL (SEQ ID NO:450).

Claim 42 (new): The peptide of claim 41, wherein said oligopeptide is GIMIGVLVGV (SEQ ID NO:149).

Claim 43 (new): The peptide of claim 41, wherein said oligopeptide is IMIGVLVGV (SEQ ID NO:193).

Claim 44 (new): The peptide of claim 41, wherein said oligopeptide is
IMIGVLVGVA (SEQ ID NO:194).

Claim 45 (new): The peptide of claim 41, wherein said oligopeptide is
LLTFWNPPT (SEQ ID NO:224).

Claim 46 (new): The peptide of claim 41, wherein said oligopeptide is
VLYGPDAPTI (SEQ ID NO:428).

Claim 47 (new): The peptide of claim 41, wherein said oligopeptide is
YLWWVNGQSL (SEQ ID NO:449).

Claim 48 (new): The peptide of claim 41, wherein said oligopeptide is
YLWWVNNQSL (SEQ ID NO:450).

Claim 49 (new): The peptide of claim 42, which is 11 amino acids in length.

Claim 50 (new): The peptide of claim 42, which is 10 amino acids in length.

Claim 51 (new): The peptide of claim 43, which is 11 amino acids in length.

Claim 52 (new): The peptide of claim 43, which is 10 amino acids in length.

Claim 53 (new): The peptide of claim 43, which is 9 amino acids in length.

Claim 54 (new): The peptide of claim 44, which is 11 amino acids in length.

Claim 55 (new): The peptide of claim 44, which is 10 amino acids in length.

Claim 56 (new): The peptide of claim 45, which is 11 amino acids in length.

Claim 57 (new): The peptide of claim 45, which is 10 amino acids in length.

Claim 58 (new): The peptide of claim 45, which is 9 amino acids in length.

Claim 59 (new): The peptide of claim 46, which is 11 amino acids in length.

Claim 60 (new): The peptide of claim 46, which is 10 amino acids in length.

Claim 61 (new): The peptide of claim 47, which is 11 amino acids in length.

Claim 62 (new): The peptide of claim 47, which is 10 amino acids in length.

Claim 63 (new): The peptide of claim 48, which is 11 amino acids in length.

Claim 64 (new): The peptide of claim 48, which is 10 amino acids in length.

Claim 65 (new): The peptide of claim 41, which is fused to a T helper peptide.

Claim 66 (new): The peptide of claim 41, which is fused to spacer or linker amino acids.

Claim 67 (new): The peptide of claim 41, which is fused to a carrier.

Claim 68 (new): The peptide of claim 41, which is linked to a lipid.

Claim 69 (new): A fusion protein comprising the peptide of claim 41.

Claim 70 (new): A homopolymer of the peptide of claim 41.

Claim 71 (new): A heteropolymer of the peptide of claim 41 and different peptides.

Claim 72 (new): A composition comprising the peptide of claim 41 and a carrier.

Claim 73 (new): A composition comprising the peptide of claim 41 and a pharmaceutically acceptable carrier.

Claim 74 (new): A composition comprising the peptide of claim 41 and a liposome.

Claim 75 (new): A composition comprising the peptide of claim 41, and one or more different peptides.

Claim 76 (new): The composition of claim 75, wherein said peptides form a fusion protein.

Claim 77 (new): The composition of claim 75, which comprises a carrier.

Claim 78 (new): The composition of claim 75 further comprising a pharmaceutically acceptable carrier.

Claim 79 (new): The composition of claim 75, wherein said peptides are fused by spacer or linker amino acids.

Claim 80 (new) An isolated peptide less than 15 amino acids in length comprising the oligopeptide LLTFWNPPV (SEQ ID NO:2223).

Claim 81 (new): The peptide of claim 80, which is 11 amino acids in length.

Claim 82 (new): The peptide of claim 80, which is fused to a T helper peptide.

Claim 83 (new): The peptide of claim 80, which is fused to spacer or linker amino acids.

Claim 84 (new): The peptide of claim 80, which is fused to a carrier.

Claim 85 (new): The peptide of claim 80, which is linked to a lipid.

Claim 86 (new): A fusion protein comprising the peptide of claim 80.

Claim 87 (new): A homopolymer of the peptide of claim 80.

Claim 88 (new): A heteropolymer of the peptide of claim 80 and different peptides.

Claim 89 (new): A composition comprising the peptide of claim 80 and a carrier.

Claim 90 (new): A composition comprising the peptide of claim 80 and a pharmaceutically acceptable carrier.

Claim 91 (new): A composition comprising the peptide of claim 80 and a liposome.

Claim 92 (new): A composition comprising the peptide of claim 80, and one or more different peptides.

Claim 93 (new): The composition of claim 92, wherein said peptides form a fusion protein.

Claim 94 (new): The composition of claim 92, which comprises a carrier.

Claim 95 (new): The composition of claim 92 further comprising a pharmaceutically acceptable carrier.

Claim 96 (new) An isolated peptide 9 or 10 amino acid residues in length comprising the oligopeptide LLTFWNPPV (SEQ ID NO:2223).

Claim 97 (new): The peptide of claim 96, which is 10 amino acids in length.

Claim 98 (new): The peptide of claim 96, which is 9 amino acids in length.

Claim 99 (new): The peptide of claim 96, which is fused to a carrier.

Claim 100 (new): A fusion protein comprising the peptide of claim 96.

Claim 101 (new): A homopolymer of the peptide of claim 96.

Claim 102 (new): A heteropolymer of the peptide of claim 96 and different peptides.

Claim 103 (new): A composition comprising the peptide of claim 96 and a carrier.

Claim 104 (new): A composition comprising the peptide of claim 96 and a pharmaceutically acceptable carrier.

Claim 105 (new): A composition comprising the peptide of claim 96 and a liposome.

Claim 106 (new): A composition comprising the peptide of claim 96, and one or more different peptides.

Claim 107 (new): The composition of claim 106, wherein said peptides form a fusion protein.

Claim 108 (new): The composition of claim 106, which comprises a carrier.

Claim 109 (new): The composition of claim 106 further comprising a pharmaceutically acceptable carrier.

Claim 110 (new): An isolated peptide less than 15 amino acids in length comprising an oligopeptide selected from the group consisting of:

VLYGPDAPTV (SEQ ID NO:2225); and

VLYGPDTPV (SEQ ID NO:2227).

Claim 111 (new): The peptide of claim 110, which is VLYGPDAPTV (SEQ ID NO:2225).

Claim 112 (new): The peptide of claim 110, which is VLYGPDTPV (SEQ ID NO:2227).

Claim 113 (new): The peptide of claim 111, which is 11 amino acids in length.

Claim 114 (new): The peptide of claim 111, which is 10 amino acids in length.

Claim 115 (new): The peptide of claim 112, which is 11 amino acids in length.

Claim 116 (new): The peptide of claim 112, which is 10 amino acids in length.

Claim 117 (new): The peptide of claim 112, which is 9 amino acids in length.

Claim 118 (new): The peptide of claim 110, which is fused to a T helper peptide.

Claim 119 (new): The peptide of claim 110, which is fused to spacer or linker amino acids.

Claim 120 (new): The peptide of claim 110, which is fused to a carrier.

Claim 121 (new): The peptide of claim 110, which is linked to a lipid.

Claim 122 (new): A fusion protein comprising the peptide of claim 110.

Claim 123 (new): A homopolymer of the peptide of claim 110.

Claim 124 (new): A heteropolymer of the peptide of claim 110 and different peptides.

Claim 125 (new): A composition comprising the peptide of claim 110 and a carrier.

Claim 126 (new): A composition comprising the peptide of claim 110 and a pharmaceutically acceptable carrier.

Claim 127 (new): A composition comprising the peptide of claim 110 and a liposome.

Claim 128 (new): A composition comprising the peptide of claim 110, and one or more different peptides.

Claim 129 (new): The composition of claim 128, wherein said peptides form a fusion protein.

Claim 130 (new): The composition of claim 128, which comprises a carrier.

Claim 131 (new): The composition of claim 128 further comprising a pharmaceutically acceptable carrier.

Claim 132,(new): The composition of claim 128, wherein said peptides are fused by spacer or linker amino acids.

Claim 133 (new): An isolated peptide less than 15 amino acids in length comprising an oligopeptide selected from the group consisting of:

ATVGIMIGV (SEQ ID NO:2159);

NLSLSCHAA (SEQ ID NO:2293);

VLYGPDDPTI (SEQ ID NO:2151);

YLSGANLNV (SEQ ID NO:2158); and

YVCGIQNSV (SEQ ID NO:2153).

Claim 134 (new): The peptide of claim 133, wherein said oligopeptide is ATVGIMIGV (SEQ ID NO:2159).

Claim 135 (new): The peptide of claim 133, wherein said oligopeptide is
NLSLSCHAA (SEQ ID NO:2293).

Claim 136 (new): The peptide of claim 133, wherein said oligopeptide is
VLYGPDDPTI (SEQ ID NO:2151).

Claim 137 (new): The peptide of claim 133, wherein said oligopeptide is
YLSGANLNV (SEQ ID NO:2158).

Claim 138 (new): The peptide of claim 133, wherein said oligopeptide is
YVCGIQNSV (SEQ ID NO:2153).

Claim 139 (new): The peptide of claim 134, which is 11 amino acids in length.

Claim 140 (new): The peptide of claim 134, which is 10 amino acids in length.

Claim 141 (new): The peptide of claim 134, which is 9 amino acids in length.

Claim 142 (new): The peptide of claim 135, which is 11 amino acids in length.

Claim 143 (new): The peptide of claim 135, which is 10 amino acids in length.

Claim 144 (new): The peptide of claim 135, which is 9 amino acids in length.

Claim 145 (new): The peptide of claim 136, which is 11 amino acids in length.

Claim 146 (new): The peptide of claim 136, which is 10 amino acids in length.

Claim 147 (new): The peptide of claim 137, which is 11 amino acids in length.

Claim 148 (new): The peptide of claim 137, which is 10 amino acids in length.

Claim 149 (new): The peptide of claim 137, which is 9 amino acids in length.

Claim 150 (new): The peptide of claim 138, which is 11 amino acids in length.

Claim 151 (new): The peptide of claim 138, which is 10 amino acids in length.

Claim 152 (new): The peptide of claim 138, which is 9 amino acids in length.

Claim 153 (new): The peptide of claim 133, which is fused to a T helper peptide.

Claim 154 (new): The peptide of claim 133, which is fused to spacer or linker amino acids.

Claim 155 (new): The peptide of claim 133, which is fused to a carrier.

Claim 156 (new): The peptide of claim 133, which is linked to a lipid.

Claim 157 (new): A fusion protein comprising the peptide of claim 133.

Claim 158 (new): A homopolymer of the peptide of claim 133.

Claim 159 (new): A heteropolymer of the peptide of claim 133 and different peptides.

Claim 160 (new): A composition comprising the peptide of claim 133 and a carrier.

Claim 161 (new): A composition comprising the peptide of claim 133 and a pharmaceutically acceptable carrier.

Claim 162 (new): A composition comprising the peptide of claim 133 and a liposome.

Claim 163 (new): A composition comprising the peptide of claim 133, and one or more different peptides.

Claim 164 (new): The composition of claim 163, wherein said peptides form a fusion protein.

Claim 165 (new): The composition of claim 163, further comprising a carrier.

Claim 166 (new): The composition of claim 163 further comprising a pharmaceutically acceptable carrier.

Claim 167 (new): The composition of claim 163, wherein said peptides are fused by spacer or linker amino acids.